Form 4 holding
Head of R&D, CMO
Syndax Pharmaceuticals Inc
- Security class
- Stock options (Right to buy)
- Shares / value
- 0
- Estimated value
- $2,956,221
- Report date
- 12 Jun 2026
- Price
- $20.43
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount